Posts by Sandra Ansanay-Alex
Startup Nights
Startup Nights, one of the largest startup event in Switzerland, is taking place on 5-6 November 2026 in Winthertur Startup Night Pitching showcases startups tackling global challenges with technologies that deliver tangible social or ecological value! A unique opportunity to gain visibility, build recognition, and showcase your solution to investors, leading innovation experts in Switzerland,…
Read MoreAzureCell Therapies secures CHF 150,000 from Venture Kick
AzureCell Therapies, a Biotech spin-off from the University of Geneva, has received CHF 150,000 from Venture Kick to deliver cell-based treatments that replace damaged neurons in Parkinson’s patients. Parkinson’s disease is an increasingly prevalent neurological disorder that affects over 10 million people worldwide. Current treatments only manage symptoms and fail to halt the disease’s…
Read Moreplanetary: The Only Swiss Finalist of the 2025 WIPO Global Awards
Out of 780 applications from 95 countries, planetary, a Geneva-Based startup specializing in sustainable food innovation, has been named the only Swiss finalist — and winner — of the 2025 WIPO Global Awards. This prestigious recognition by the World Intellectual Property Organization (WIPO) honors small and medium-sized enterprises (SMEs) leveraging intellectual property to tackle…
Read MoreFriedrich Miescher Award
If your are a researcher in biochemistry, apply before 18 October 2026 for the Friedrich Miescher Award To commemorate the 100-year anniversary of the discovery of nucleic acids the Molecularand Cellular Biosciences section of Life Sciences Switzerland (formerly the Swiss Society for Molecular and Cellular Biosciences/Swiss Society for Biochemistry) has created the Friedrich Miescher Award.…
Read MoreCREAL Closes $8.9M Investment Round Led by ZEISS
CREAL, the Vaud-Based innovator behind revolutionary light field display technology, announces the final closing of an $8.9 million equity funding round, led by ZEISS, with participation from new and existing investors, including members of the UBS private investor network. CREAL’s latest investment round underscores the growing momentum around light field technology and its potential…
Read MoreCleantechAlps Celebrates 15 Years of Accelerating Sustainability Innovation in Western Switzerland
CleantechAlps, the regional hub for clean technologies in Western Switzerland, is marking 15 years of dedicated support to sustainability and cleantech innovation. Launched in 2010 by the cantons of Western Switzerland, the platform has become a strategic catalyst for collaboration, promotion, and development across the cleantech ecosystem in Switzerland and Europe. From its inception,…
Read MoreParkinson’s Disease: How the First Affected Side Shapes the Course of Symptoms
New research from the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) reveals that the side of the body where Parkinson’s disease first manifests plays a critical role in the development of non-motor symptoms such as cognitive decline, anxiety, and depression. Parkinson’s disease, which affects over 10 million people globally, typically begins asymmetrically—impacting…
Read MoreLara Chavaz from HUG Wins Swiss Childhood Cancer Research Award
The official award ceremony for the Swiss Childhood Cancer Research Prize took place in Bern on 18 June 2025, recognizing Lara Chavaz of the Geneva University Hospitals (HUG) for her outstanding contribution to pediatric oncology research. The CHF 35,000 prize honors innovative projects in basic research conducted at Swiss research institutes and hospitals. …
Read MoreUNIL Scientists Develop Innovative Method to Reverse Cellular Aging
A team of researchers at the University of Lausanne (UNIL) has unveiled a groundbreaking approach to combat cellular aging using a non-genetic, chemical-based method. Published in EMBO Molecular Medicine, their study demonstrates how a short treatment with a specific combination of small molecules can rejuvenate aged human cells and extend lifespan in microscopic worms, opening…
Read MoreComphya Closes Oversubscribed CHF 7.5 Million Series A Round
Comphya SA, a Vaud-based clinical-stage MedTech company pioneering the first implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication, announced the closing of an oversubscribed Series A financing round. Including the conversion of existing convertible loans, the round brings Comphya’s total equity raised to CHF 7.5 million (~USD 8.4 million). “We are…
Read More